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1. Introduction 
Hypertrophic cardiomyopathy (HCM) is a common structural anomaly of the myocardium 
that is unexplained by an underlying condition such as hypertension. The main findings in 
HCM are varying degrees of ventricular and/or septal hypertrophy, myocyte disarray and 
increased myocardial fibrosis (Maron et al., 1995). There is significant variation in the 
clinical manifestation among patients, from asymptomatic, to mild dyspnea upon exertion, 
to substantive heart failure. While many individuals will present with clinical symptoms, 
including a cardiac murmur related to outflow tract obstruction, in some families, diagnosis 
is not established until the sudden death of, or incidental finding of hypertrophy within, a 
family member. Transthoracic echocardiography has traditionally been the clinician’s 
primary tool for determination of asymmetric hypertrophy of the left interventricular 
septum, with or without left ventricular outflow tract obstruction. Given the heterogeneity 
in severity of disease and penetrance within HCM-affected families, it is important to rule 
out other secondary causes of hypertrophy, such as hypertension or aortic stenosis. 
Diagnosis can be difficult, especially in elite athletes who may present with physiological 
left ventricular hypertrophy (Maron, 2009). Clinically identifiable HCM has a prevalence of 
1:500 in young adults in the general population, making it the most common genetic 
cardiovascular disease in many countries (Maron et al., 1995).  
Although familial hypertrophic cardiomyopathy (FHC) was first described clinically more 
than half a century ago (Teare, 1958), it was only about 20 years ago that the underlying 
molecular causes of FHC began to be established, with the finding of a mutation in the beta-
myosin heavy chain (MYH7) gene (Geisterfer-Lowrance et al., 1990). Since this seminal 
discovery, there have been more than 900 different mutations identified in over 20 FHC 
candidate genes (Tester & Ackerman, 2009). Historically, attempts to establish the link 
between genotype and phenotype were based on studying FHC cohorts with severe, well 
established disease with cardiac remodelling and in some patients, progression to end-stage 
cardiac dilatation and failure. It is increasingly apparent that focussing on the end 
phenotype as a link to genotype is problematic; families are highly heterogeneous in their 
disease presentation with, in many cases, low penetrance (at least on echocardiography 
diagnoses) and with novel mutations not seen in other families. There are few large FHC-
affected families, leading to linkage analysis difficulties. When a pathogenic FHC mutation 
is uncovered in the proband, genetic testing of all first degree relatives is highly 
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recommended. When other family members are genotyped, mutation-positive relatives can 
be closely monitored for disease progression (Colombo et al., 2008).  
Up to 60% of patients with a high index of suspicion for FHC are found to have a genetic 
mutation in one of the FHC-susceptibility genes. A subset of FHC patients do not have 
identifiable mutations, perhaps because of reduced screening sensitivity that does not 
incorporate deep intronic sequencing, identify large insertions or deletions in the known 
candidate genes or include non-hot spot encoding regions. In addition, some patients may 
have mutations in as-yet unrecognized candidate genes (Rodriguez et al., 2009). The 
majority of documented FHC mutations occur as single nucleotide substitutions or 
“missense” mutations, although nucleotide deletions and insertions have also been 
identified. Insertions and deletions can potentially truncate the gene product by causing a 
shift in the reading frame leading to a premature stop codon. Mutations that occur at 
exon/intron boundaries can cause splice anomalies, leading to abnormal and potentially 
dysfunctional protein products (Wheeler et al., 2009).  
Two prominent hypotheses have been developed to explain how sarcomere protein 
mutations cause the FHC phenotype: first is the “poison polypeptide” hypothesis, in which 
a single mutant protein disrupts the function of the entire sarcomere unit in a dominant 
negative manner (Thierfelder et al., 1994). The mutant protein is translated and incorporated 
into the sarcomere, where it can impair contraction. The second hypothesis is that 
sarcomeric protein mutations can lead to haploinsufficiency, in which mutations disrupt one 
copy of the gene, leaving the wild-type gene copy to produce the protein product in 
inadequate quantities for a balanced sarcomere unit (Thierfelder et al., 1994). In this 
situation, there is a 50% reduction in peptide concentration due to disruption in translation 
or trafficking of the mutant. Inadequate levels of incorporated wild-type protein create an 
imbalance in thin filament stoichiometry.  
2. Sudden cardiac death in FHC 
FHC is the most common cause of sudden cardiac death (SCD) in young people, affecting 
approximately 1-2% of children and adolescents, and up to 1% of young adults in HCM 
community cohorts (Elliott et al., 2000; Maron, 2002). Although SCD is considered rare in 
competitive athletes (1 in 200,000), HCM is associated with nearly one third of such 
occurrences (Maron, 2003). Children have the highest SCD rates of FHC patients suggesting 
that early onset can result from a more severe phenotype that includes lethal arrhythmias 
(Maron et al., 1999; Ostman-Smith et al., 2008). The highest mortality rates are seen in 
children aged 9 to 14 years, averaging 7.2%. The SCD risk peaks in girls at 10 to 11 years of 
age and occurs in boys at 15 to 16 years of age, leading to some researchers to propose that 
the surge in androgens that occurs prior to puberty may be associated with rapid disease 
progression and increased SCD risk (Ostman-Smith et al., 2008). There is a male 
preponderance for FHC-related SCD, especially among athletes (Maron et al., 1996). FHC 
patients with 2 or more mutations (Hershberger, 2010; Van Driest et al., 2004), and 
homozygous mutation patients, have more severe disease phenotypes with higher 
penetrance and greater incidence of SCD over single mutation patients (Ho et al., 2000; 
Ingles et al., 2005). Modifier gene polymorphisms such as angiotensin I converting enzyme 
(ACE) D allele, (Marian et al., 1993) and lifestyle/environmental factors such as diet, 
exercise, body mass and hypertension may also affect the FHC phenotype. With such 
complexities in disease manifestation, SCD risk assessment has been problematic. Younger 
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age at onset, history of syncope with exertion, history of SCD within close relatives, severity 
of symptoms and degree of ventricular and septal wall thickness have been used in risk 
stratification algorithms; however, many risk factor studies involved non-genotyped 
patients with sometimes conflicting or confusing results and frequently with no single risk 
factor being identified. Prognosis for genotyped patients varies with the gene and in many 
cases, specific mutations within a gene; however, the mechanisms by which such mutations 
have an increased propensity for sudden death in some individuals, while in others appear 
to be relatively benign, are not well understood. The primary prevention risk factors for 
SCD in FHC include family history of SCD, unexplained recent syncope, runs of non-
sustained ventricular tachycardia on ambulatory 24 hour Holter monitor, hypotensive 
response to exercise and severe left ventricular wall thickness (over 30 mm) (Maron, 2010). 
With respect to the latter, mild ventricular hypertrophy, however, does not correlate with 
low SCD risk, especially with thin filament mutations, as discussed later. 
3. The role of the troponin complex in cardiac dynamics 
The focus of this chapter is on three genes that encode the troponin complex found within 
the sarcomere; TNNT2, encoding cardiac troponin T, TNNI3, encoding cardiac troponin I 
and TNNC1, encoding troponin C. These genes encode the cardiac troponin genes that are 
unique from their skeletal counterparts and have evolved to help regulate excitation-
contraction coupling in the heart. The troponin (Tn) proteins are part of a thin filament 
regulatory unit of the sarcomere. Cardiac troponin C (cTnC) is the Ca2+-binding subunit 
that acts as a cytosolic Ca2+ sensor, cardiac troponin I (cTnI) is the inhibitory subunit that 
inhibits contraction when intracellular Ca2+ levels are below activation levels and cardiac 
troponin T (cTnT) is the subunit responsible for attaching the troponin complex to the thin 
filament via binding with tropomyosin (Tm) and believed responsible for movement of 
Tm on the thin filament modulating binding of the myosin head to actin. The subunits are 
arranged in a 1:1:1 stoichiometric ratio along the thin filament with one Tn:Tm complex 
bound to every seven actin monomers. Actin monomers are arranged in a double helix 
oriented in parallel to myosin-containing thick filaments. These protein-protein 
configurations allow for thin filament activation (Figure 1), which in turn facilitates cross-
bridge cycling through the action of myosin binding to actin and the production of force 
(Gordon et al., 2000). 
Takeda and collaborators (Takeda et al., 2003) successfully crystallized the globular core 
of the Tn complex, which revealed that the complex is highly flexible, an inherent feature 
crucial to its role in heart muscle contraction. The structure consists of two domains: the 
regulatory head composed of the N-terminus of TnC (residues 3 – 84) and two ǂ-helices of 
TnI (denoted as H3 and H4, residues 150 - 188), and the highly conserved IT arm 
composed of the C-terminus of TnC (residues 93-161), two ǂ-helices of TnI (H1 and H2, 
residues 42-136) and two ǂ-helices of TnT (H3 and H4, residues 203-271). Although 
crystallography allowed most of the Tn complex structure to be observed, some regions 
remain unresolved, including the inhibitory region of TnI, and both the N- and C-terminal 
regions of TnT. These regions are likely highly flexible, allowing them to bind to other 
thin filament proteins (i.e. actin) to modulate thin filament activation. The primary role of 
the regulatory domain is as the “Ca2+ sensor”, while the rigid IT domain appears to be 
sensitive to myosin binding during contraction (Sun, Bradmeier & Irving, 2006, as cited in 
Willott et al., 2010).  
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Fig. 1. A schematic representation of cardiac troponin in relation to the thin filament in the 
absence and presence of Ca2+. The inhibitory region of TnI (IR), and the N-terminal and C-
terminal domains of TnT are not clearly observed in the crystal structure, likely due to their 
inherent flexibility (see text). The red dots represent Ca2+ ions. The figure is adapted from 
Takeda, 2003 (Li, 2009). 
Most researchers believe that a “3 state model” exists to explain myofilament contraction. 
Interestingly, it was the study of how various mutations disrupt these interactions that lead 
to further development and confirmation of the 3 state model (Gordon et al., 2000). During 
diastole, the ventricles fill with blood to their end-diastolic volumes. The sarcomeres are 
stretched to longer lengths but without developing significant diastolic pressures. Cross-
bridge cycling is physically blocked by the Tm:Tn complex at this stage and is referred to as 
the “blocked” or “B” state. Recently it has been postulated that perhaps only 50% of the 
cross-bridges are sterically blocked. The rest may be in a weakly-bound non-force 
generating state that facilitates the transition of cross-bridge cycling into the systolic state. 
There are two actin-binding regions on cTnI that play an essential role in diastole. There is 
an inhibitory region (residues 137-148) and a downstream helix (H3, residues 150-159) that 
tightly binds to actin, which along with cTnT, anchor Tm into the blocking position (see 
review by Parmacek & Solaro, 2004). 
Calcium initially enters the cell mainly through L-type Ca2+ channels and initiates Ca2+-
induced Ca2+ release from the sarcoplasmic reticulum. As cytosolic Ca2+ levels rise, the 
sarcomeres develop tension that increases ventricular isovolumic pressure until the aortic 
and pulmonary valves open. Blood is expelled from the ventricles by sarcomeres shortening 
to their end-systolic lengths. At the subcellular level, myofilament activation begins with 
Ca2+ binding to cTnC site II, exposing a hydrophobic region at the N lobe of cTnC and 
creating a new binding site for cTnI. Cardiac TnI then dissociates from actin and binds 
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tightly to the hydrophobic region of cTnC, causing a cascade of protein-protein interactions 
that allows Tm to move closer into the thin filament groove. This stage is referred to as the 
“closed” or “C” state. This movement exposes myosin binding sites on actin and also 
appears to alter thin filament structure, allowing more cross-bridges to occur and moving 
Tm further into the thin filament groove (thus shifting into the “open” or “M” state). 
Positive feedback may arise from bound cross-bridges causing an increased affinity for Ca2+ 
by cTnC (Pan & Solaro, 1987 as cited in Solaro & Kobayashi, 2011). At basal states of 
contractility, only 25% of available cTnC regulatory (site II) Ca2+ binding sites are occupied 
due to low cytosolic Ca2+ levels, resulting in a substantial cardiac reserve for recruitment of 
blocked cross-bridges when required.  
After the valves close, the sarcomeres are quiescent as the ventricles prepare for refilling. 
This relaxation phase is highly dependent upon the rate of cytosolic Ca2+ removal, the off-
loading of Ca2+ from cTnC, and the cross-bridges returning to the weakly bound or blocked 
state. Phosphorylation of the thin filament proteins, in particular the N-terminus of cTnI, 
plays a crucial role in drawing upon cardiac reserve, cross-bridge cycling rate and hence, 
relaxation, in a signaling cascade initiated by ǃ-adrenergic stimulation (see review by 
Tardiff, 2011). These mechanisms are critically important when increased heart rate is 
required during exercise. Considering that SCD in young FHC patients frequently occurs 
during exercise (Cha et al., 2007), thin filament mutations may have an inhibitory effect on 
phosphorylation signalling and cardiac reserve as well as other cross-bridge cycling effects. 
4. Mechanisms of Sudden Cardiac Death in FHC troponin mutations 
Various mechanisms for SCD due to FHC have been suggested including arrhythmias 
arising from sinus nodal and atrioventricular nodal conduction abnormalities, and 
tachycardia due to re-entrant depolarization pathways from myocardial disarray and 
fibrosis, abnormal Ca2+ homeostasis, ventricular diastolic dysfunction or left ventricular 
outflow tract obstruction (Fatkin & Graham, 2002). With several underlying mechanisms 
leading to SCD, research is only beginning to define the link between the underlying 
molecular pathology and arrhythmogenesis in FHC-associated troponin mutations.  
One emerging issue is that studying patients with well established disease for the purpose 
of linking phenotype to genotype has proven extremely difficult. Like all monogenic 
disorders, there are myriad disease modifiers including genetic, environmental and lifestyle 
factors that influence disease progression and severity in a manner that is poorly 
understood. What is also becoming apparent is that ventricular hypertrophy, fibrosis and 
obstructive disease are likely compensatory FHC features and based on complex signalling 
cascades arising from pathologies within the sarcomere, as discussed later in this chapter. 
Perhaps longitudinal studies of patients prior to the onset of structural disease may uncover 
mutation-specific disease progression that parallels the molecular and biophysical effects 
observed in in vitro experiments, animal models and in silico predictions (Tardiff, 2011). 
There is likely a less complex phenotype in FHC patients in the early disease stages allowing 
a more discernable link between genotype and phenotype. A study of preclinical FHC 
patients provides evidence for this hypothesis (Ho et al., 2002). In their study, most FHC 
cohorts presented with one common phenotype, namely prolonged diastolic relaxation on 
echocardiography, despite patients having different mutations within different genes. This 
approach may also benefit treatment outcomes for preclinical FHC cohorts with targeted 
mutation-specific treatment to attenuate disease progression. It makes sense to treat pre-
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symptomatic FHC patients long before gross phenotype becomes established. Diltiazem, a 
calcium channel blocker, normalized Ca2+ regulation and attenuated ventricular 
hypertrophy in a mouse model (Semsarian et al., 2002) and formed the basis of an ongoing 
clinical trial, in which preclinical FHC patients receive diltiazem therapy while being 
monitored for disease progression (http://clinicaltrials.gov/ct2/show/NCT00319982).  
Recent approaches to identifying the pathophysiology of FHC mutations includes 
investigation of the dynamic properties of cross-bridge cycling at the molecular level and 
how Tn mutations disrupt precise molecular movements. Such high resolution 
investigations commonly incorporate computational approaches to examine protein 
flexibility and to predict changes in protein mobility caused by mutations, using molecular 
dynamics simulation programs such as GROMACS (Van Der Spoel et al., 2005) and 
CHARMM (Brooks et al., 2009). Another approach is Nuclear Magnetic Resonance (NMR) 
imaging, allowing investigators to compare recombinant wild-type and mutated Tn 
complexes in different metal-binding states to measure conformational changes (Lassalle, 
2010).  
4.1 Troponin T mutations  
Since the identification of cTNNT2 in 1993 as the first Tn-based gene associated with FHC 
(Thierfelder et al., 1993), cTnT mutations have been extensively studied and account for up to 
15% of all FHC mutations (Watkins et al., 1995). To date, there are at least 68 cTnT mutations 
identified associated with FHC (Willott et al., 2010), with a subset that present with a high 
frequency of SCD and/or ventricular arrhythmia in humans (Table 1). Alternative splicing of 
exons 4 and 5 of the cTNNT2 gene in the human heart results in four temporally regulated 
isoforms: one adult isoform (TnT3) and 3 fetal isoforms (TnT1,TnT2 and TnT4). The variable 
cTnT N-domain contributes to the Ca2+ sensitivity of force development and the presence of 
fetal isoforms in adult myofilaments has been associated with increased myofilament Ca2+ 
sensitivity and diastolic dysfunction (Gomes et al., 2002 as cited in Gomes et al., 2004). Tn 
complexes with fetal isoforms TnT1 and TnT2 (containing exon 5) have a reduced inhibition of 
actomyosin ATPase activity compared with the adult TnT3 isoform which suggests that the 
TnT isoforms have varying ability to modulate cross-bridge cycling and hence, cardiac 
contraction (Gomes et al., 2002). These findings are noteworthy in that increased myofilament 
Ca2+ sensitivity and diastolic dysfunction occur with many FHC causing Tn mutations; 
however, studies investigating the expression of cTnT isoforms in diseased hearts and a 
possible contributory role in altered contractile performance remain unresolved with no as-yet 
obvious correlation between fetal isoform TnT4 expression and Ca2+ sensitivity in diseased 
hearts (see review by Parmacek & Solaro, 2004). 
The majority of cTnT mutations occur within the two structurally poorly resolved regions with 
a clustering of mutations within residues 69 to 110. There are three “hot spots” occurring at 
residues 92, 94 and 110, of which R92L and F110I have been associated with high rates of SCD 
and/or ventricular arrhythmia (Table 1). Another mutational “hotspot” occurs at residues 160 
to 163, which is found within a highly charged and a highly conserved sequence from 157 to 
166. This region is believed to be a flexible linker between H1 and H2 and whose structure has 
so far eluded resolution. Closer to the C terminus is a scattering of mutations associated with 
dilated cardiomyopathy (DCM) as well as several FHC mutations. It is believed that residues 
in this particular region affect Ca2+ sensitivity via allosteric interactions with the cTnC C 
domain, although actual evidence is lacking (Tardiff, 2011).  
www.intechopen.com










I79N, F87L, R92L, 
R92W, R94L, A104V, 
∆E160*, S179F, Intron 
16G1→AŦ 
SCD 
(Gimeno et al., 2009; 
Knollmann & Potter, 2001; 
Moolman et al., 1997; 
Thierfelder et al., 1993; 




(Watkins et al., 1995) 
cTnI 
R145G, A157V, R162Q, 
∆K183*, R186Q, S199N SCD 
(Ashrafian et al., 2003; 
Niimura et al., 2002; Van 




(Alcalai et al., 2008; 
Ashrafian et al., 2003) 
cTnC Q122AfsX30¥ SCD (Chung et al., 2011) 
Table 1. Troponin mutations associated with SCD and ventricular arrhythmia. *∆ denotes 
deletion of the noted residue causing an in-frame mutation; Ŧ denotes a splice donor site 
mutation that removes 28 residues at the C terminus and replaces them with 7 nonsense 
codons resulting in a truncated cTnT mutant; ¥ denotes a nucleotide duplication (G) at 
position 363, causing a frame-shift substitution on residue 122 (Q122A) and a premature 
stop codon (X) at residue 30 resulting in a truncated cTnC mutant. 
4.1.1 In vitro and in vivo approaches, animal models and in silico predictions 
Cardiac TnT mutations are predicted to affect the regulatory role of the Tn-Tm complex on 
sarcomere activation given that TnT functions to attach the Tn complex to Tm and actin 
(Tobacman, 1996). In vitro studies with different FHC mutations (including cTnT mutants) 
show faster contraction kinetics and increased Ca2+ sensitivity of force generation. Some 
studies show increased sarcomeric activation at lower Ca2+ levels, resulting in myofilament 
activation and contraction at shorter sarcomere lengths against an increased passive force 
(Haim et al., 2007; Tardiff et al., 1999). The shorter baseline sarcomere length may be an 
important factor in why cTnT R92Q transgenic mutant mice have smaller myocytes and 
negligent or minimal ventricular hypertrophy (Tardiff et al., 1999).  
Abnormal Ca2+ homeostasis may result from a variety of factors including altered Ca2+ 
availability and altered myofibrillar Ca2+ sensitivity. In vitro studies of skinned myocardial 
fibres reconstituted with mutant cTnT mutations (I79N, R92Q, F110I, ∆E160) show increased 
myofilament Ca2+ sensitivity, which researchers postulate is an important mechanism for 
the high incidence of SCD even with mild or absent hypertrophy and fibrosis (Gomes & 
Potter, 2004a; Gomes & Potter, 2004b; Knollmann & Potter, 2001). In silico studies based on 
results from in vivo transgenic I79N cTnT mouse fibres predict a higher basal contractility, 
increased rate of force development, delayed relaxation and increased resting tension 
compared with wild-type fibres (Miller et al., 2001).  
In intact transgenic mouse hearts and in isolated voltage-clamped cardiomyocytes, 
Knollmann et al. produced compelling evidence that ventricular arrhythmias may arise 
from action potential remodelling related to altered Ca2+ regulation in mice carrying the 
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human cTnT I79N mutation (Knollmann et al., 2003). A more recent study elegantly 
demonstrated that the degree of myofilament sensitivity may be correlated positively 
with the risk of developing ventricular tachycardia (Baudenbacher et al., 2008). Given 
that the transgenic mice had no evidence of hypertrophy, fibrosis or myocyte disarray, 
this study provided further evidence that altered myofilament function is the underlying 
pathophysiological mechanism of FHC and may be the causal link of FHC to SCD. Many 
of the most “deleterious” cTnT mutations are located within the H1 domain of the N-
terminus. Previous studies have demonstrated that the N-terminus plays an important 
role in the inhibition of myofilament activation (reviewed in Tardiff, 2011). It stands to 
reason that disruption of this inhibitory N-terminal function by mutations in this region 
may allow Tm movement (and hence, cross-bridge cycling) under conditions of low Ca2+, 
exhibiting an apparent increased Ca2+ sensitivity of myofilament activation (Tardiff, 
2011).  
4.1.2 Human cardiac TnT mutation studies 
FHC patients harbouring the I79N cTnT mutation commonly present with minimal or 
absent hypertrophy on echocardiography and are frequently asymptomatic (i.e. no 
syncope, dyspnea or chest pain at rest or with exertion), yet have the highest incidence of 
SCD among young cTnT mutation carriers (Watkins et al., 1995) and is one of the most 
investigated of all FHC mutations (see review by Gomes et al., 2004). The F87L mutation 
also presents with mild hypertrophy (less than 16 mm ventricular wall thickness) but with 
a high incidence of SCD, including sub-adult patients, in a study of one multigenerational 
family (Gimeno et al., 2009). Of great significance, the youngest mutation carriers were 
completely asymptomatic. The R94L was also studied within a single family and found to 
have marked myocyte disarray and frequent SCD in the absence of ventricular 
hypertrophy (Varnava et al., 1999 as cited in Gomes et al., 2004). FHC patients with the 
A104V cTnT mutation also have a high incidence of SCD with only moderate left 
ventricular hypertrophy (Szczesna et al., 2000 as cited in Gomes & Potter, 2004; Gomes et 
al., 2004). A longitudinal study involving R92W cTnT FHC patients revealed that 
clinically identifiable hypertrophy did not occur in this cohort until after 35 years of age 
and yet the highest occurrence of SCD was prior to cardiac remodelling, particularly in 
young males (Revera et al., 2007, as cited in Revera et al., 2008). Another study by the 
same group (Revera et al., 2008) reported that phenotype-negative R92W patients had 
higher basal contractility and delayed relaxation compared to their genotype-negative 
relatives. Given the mild phenotype of many cTnT mutation patients, there is likely a 
reporting and referral bias in these patients and are therefore likely under-recognized in 
FHC clinics where the majority of patients have substantial hypertrophy and outflow 
obstruction that are relatively easy to diagnose non-invasively by echocardiography 
(Tardiff, 2011). 
A study comparing FHC cTnT mutation patients with other FHC patients who died 
suddenly revealed that the cTnT mutation patients were younger, had less hypertrophy 
and fibrosis, but more myocardial disarray than other patients (Varnava, Elliott, 
Baboonian et al., 2001). Such findings suggest that the pathological mechanism is 
essentially myocellular as opposed to being related to the sequelae of ventricular 
hypertrophy and that ventricular wall thickness may not be an appropriate risk factor for 
SCD in cTnT patients.  
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4.2 Troponin I mutations 
The first report of FHC-causing mutations in the TNNI3 gene was in 1997 (Kimura et al., 
1997), in which 5 missense mutations were discovered that co-segregated with FHC. Since 
then, approximately 35 mutations have been reported linked to FHC, of which several 
missense and deletion mutations are associated with SCD and/or ventricular arrhythmia 
(Table 1). There are 3 genes encoding 3 TnI protein isoforms, of which two are expressed in 
the human heart on a temporal basis. The slow skeletal TnI (ssTnI from the TNNI1 gene) is 
the predominant isoform expressed within the fetal heart. This isoform declines rapidly 
after birth and is generally replaced by the cardiac isoform (cTnI from the TNNI3 gene) by 
approximately 9 months of age in humans (Bhavsar et al., 1991, Hunkeler, Kullman and 
Murphy, 1991 and Sasse et al., 1993 in Parmacek & Solaro, 2004). The 31 residue N-terminus 
in cTnI is entirely absent in ssTnI and contains two serine residues at positions 23 and 24, 
that are substrates for phosphorylation by protein kinase A (PKA). Given that PKA 
phosphorylation of these serine residues reduces myofilament Ca2+ sensitivity and 
accelerates cross-bridge cycling during high heart rates (see below), it is not surprising that 
fetal myofilaments have an increased Ca2+ sensitivity and reduced length dependence of 
Ca2+ activation (Arteaga et al., 2000, Fentzke et al., 1999 and Wolksa et al., 2001 as cited in 
Parmacek & Solaro, 2004). However, increased ssTnI expression is not observed in hearts 
with severe FHC phenotype (Sasse et al., 1993 as cited in Parmacek & Solaro, 2004), 
suggesting that other factors, such as myocellular modifications due to FHC mutations, are 
at play. 
The clustering of FHC mutations within the highly flexible inhibitory domain and the 
mobile region of cTnI with its actin-Tm binding site are of extreme interest to researchers. 
Perhaps this clustering represents a “tolerance” to alterations of the highly mobile regions of 
the thin filament, providing evidence that Tn mutations frequently modulate, but do not 
obliterate, thin filament movements. Some researchers have proposed that under sub-
maximal cardiac loads, many of the discussed mutations are relatively benign. However, 
increased cardiac loads can create the arrhythmogenic substrate leading to SCD in a subset 
of FHC patients, which is in keeping with the observed high frequency of SCD occurring 
during or following physical activity (Maron, 2003).  
PKA phosphorylation of cTnI affects the cross-bridge cycling rate in response to ǃ-
adrenergic activation and represents a post-translational mechanism through which 
mutations can cause adverse effects to cardiac output and response to increased cardiac 
demands. Phosphorylation of cTnI at S23 and S24 causes a decrease in Ca2+ sensitivity of 
force generation, increase in off-rates of Ca2+ from TnC site II, increase in cross-bridge 
cycling rate and increase in relaxation rate (Metzger & Westfall, 2004 in Tardiff, 2011). 
Functional studies with the FHC cTnI R145G mutation provide evidence of an interaction 
between the N-terminus and the inhibitory domain of cTnI, as the expected desensitization 
after PKA-mediated phosphorylation was not observed with this mutant. Perhaps the loss of 
a basic residue (arginine to glycine) depresses inhibition in the inhibitory domain and alters 
electrostatic interactions with the N-terminal of cTnI (Deng, Y. et al., 2001 as cited in Tardiff, 
2011). 
4.2.1 In vitro and in vivo approaches 
Similar to other FHC mutations, cTnI mutations demonstrate increased myofilament Ca2+ 
sensitivity which is believed to contribute to pathological hypertrophy and SCD (Parmacek 
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& Solaro, 2004). Elliot et al. (2000) reported that R145G and R162G mutations demonstrated 
significantly increased Ca2+ sensitivity of ATPase regulation (i.e. force generation) and 
reduced inhibition of actomyosin ATPase activity in vitro. Skinned reconstituted rabbit 
fibres incorporating R145G, R162G and ΔK183 mutants provide further evidence with 
increased Ca2+ sensitivity consistent with myofilament activation at lower Ca2+ levels and 
predicting an impairment in cardiac relaxation (Takahashi-Yanaga et al., 2001). An in vivo 
study with a cTnI R145G transgenic mouse model also confirmed these results (James et al., 
2000). Other animal models recapitulate human FHC findings of myocellular dysfunction 
preceding structural phenotype; young transgenic cTnI G203S mice display abnormal Ca2+ 
cycling with prolonged decay rates of Ca2+ transients long before phenotypic expression of 
hypertrophy, fibrosis and myocyte disarray (Tsoutsman et al., 2006). Transgenic rabbits 
expressing low protein levels of R145G cTnI displayed apical myocyte disarray, interstitial 
fibrosis, but with only mild ventricular hypertrophy at later ages (1.5 to 2 years of age) 
(Sanbe et al., 2005). Rabbit models more closely resemble human cardiac physiology in that 
myocellular Ca2+ handling and alterations in Ca2+ flux during heart failure is much more 
similar to humans than mouse models (Bers, 2002, as cited in Sanbe et al., 2005). Another 
limitation for mouse models is their heart rate is roughly 10 times faster than humans, which 
in turn influences the refractory period associated with arrhythmia incidence (Boyett and 
Jewell, 1978 as cited in Sanbe et al., 2005). 
4.2.2 Human cardiac TnI mutation studies 
As with cTnT mutations, studies into patients with cTnI mutations are confounded by small 
family sizes and referral biases. Nonetheless, characterization of the ∆K183 mutation in 
several families lead to striking discoveries of high penetrance, age-independent SCD and 
highly variable ventricular remodeling with some patients, particularly in patients over 40 
years, progressing to left ventricular dilatation (referred to as “burned out” hypertrophic 
cardiomyopathy) within single, multigenerational families (Kokado et al., 2000). A 
landmark study (Mogensen et al., 2004) reported the phenotype with 748 families ranging 
from severe restrictive cardiomyopathy, biventricular hypertrophy, or apical hypertrophy in 
some relatives to no disease features in others, complicating treatment options and risk 
stratification within families and suggesting that other genetic and/or environmental factors 
play a role in disease manifestation (Parmacek & Solaro, 2004). Unlike cTnT mutations, 
however, there have been no reported cases of SCD with mild disease presentation 
(Mogensen et al., 2004). Interestingly, most of the 13 cTnI mutations within this large cohort 
are found with the relatively narrow range of exons 7 and 8 encompassing the inhibitory 
and mobile domains of the C terminal domain.  
4.3 Troponin C mutations 
Cardiac TnC has only recently joined the list of FHC-causing genes and so far, 6 mutations 
have been identified (Chung et al., 2011; Chung et al., 2011; Hoffmann et al., 2001; 
Landstrom et al., 2008; Willott et al., 2010). Cardiac TnC is a highly conserved protein found 
in all striated muscle among vertebrate species. In mammals, there are two paralogs of TnC: 
the fast skeletal TnC (sTnC) and the cardiac/slow skeletal TnC (cTnC), consisting of N- and 
C-terminal domains connected by a long central ǂ-helix. Each domain contains a pair of EF-
hand (helix-loop-helix) motifs that bind Ca2+ (Kretsinger & Nockolds, 1973, as cited in Li, 
2009) and are numbered I to IV (Potter & Gergely, 1975; Zot & Potter, 1982 as cited in Li, 
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2009). Site III and site IV in the C-terminal domain have high Ca2+ binding affinity and are 
generally occupied by Mg2+ and Ca2+ ions under physiological conditions. Thus, the C-
terminal domain almost always adopts a more open conformation, making it a “structural” 
domain that maintains the integrity of the Tn complex (Potter & Gergely, 1975; Zot & Potter, 
1982 as cited in Li, 2009). The N-terminal domain exhibits a lower Ca2+ binding affinity of 
106 M-1 (more than one order of magnitude lower affinity than sites III and IV) and is 
therefore sensitive to changes in cytosolic Ca2+ concentration, making it the “regulatory 
domain” (Potter & Gergely, 1975; Zot & Potter, 1982 as cited in Li, 2009). It was proposed 
that the N-terminal domain changes from a “closed” state to an “open” state upon Ca2+ 
binding. A reorientation of helices exposes the hydrophobic residues of the central helix, 
where the inhibitory domain of TnI binds and triggers the overall conformational change of 
the Tn complex. As cTnC does not have a functional Ca2+ binding site I, it tends to have a 
more closed conformation compared to sTnC even when site II is coordinating Ca2+ 
(Herzberg, Moult & James, 1986 in Li, 2009). 
4.3.1 In vitro analyses and human cardiac TnC mutation studies 
What makes cTnC mutations unique is that they are dispersed relatively evenly throughout 
the gene. As with other Tn mutations, investigations into cTnC mutations are confounded 
by small family sizes and in some cases, are limited to a single patient. Commercial and 
research laboratories have only recently added cTnC to their molecular genetic testing 
platforms (and some continue to omit cTnC from their screenings), leading one to propose 
perhaps some purportedly genotype-negative FHC patients could potentially harbour cTnC 
mutations.  
The first observed FHC related cTnC mutation, L29Q, was discovered in a 59 year old man 
who presented with dyspnea upon exertion (Hoffmann et al., 2001). An ECG revealed an 
abnormal QRS complex suggestive of ventricular hypertrophy and confirmed by 
echocardiography. There has yet to be any follow-up study with this patient who would 
now be approximately 70 years of age, which limits knowledge of disease progression with 
this mutation. 
Leucine 29 of cTnC is located in the dysfunctional Ca2+ binding site I of the N-domain. 
Although it is not Ca2+ binding, it is important in maintaining the structural integrity of the 
first helix of cTnC (Sia et al., as cited in Li, 2009). It is located at the cTnI binding site 
(Schmidtmann et al., 2005). Replacement of a non-polar leucine with a polar glutamine is 
predicted to have an impact on overall function of the Tn complex with Tm. However, 
several studies show that in the absence of phosphorylated cTnI, the L29Q mutation can 
decrease, increase, or have no affect on Ca2+ sensitivity (Baryshnikova et al., 2008; Liang et 
al., 2008; Schmidtmann et al., 2005) leading to scepticism of its status as a pathogenic FHC 
mutation. For example, in vitro assays conducted on L29Q show that the Ca2+ sensitivity of 
ATPase in reconstituted thin filaments is not affected by PKA-dependent phosphorylation 
of cTnI (Schmidtmann et al., 2005). This finding implies that L29Q may decrease the Ca2+ 
sensitivity and disrupt the signal from the phosphorylated cTnI to cTnC. However, this 
finding contradicts other reports of FHC mutations generally having higher myofilament 
Ca2+ sensitivities (Chang et al., 2005; Gomes & Potter, 2004; Karibe et al., 2001). Recent NMR 
and ultraviolet/visual spectrum titration studies showed that L29Q essentially has the same 
Ca2+ affinity as that of wild-type cTnC (Baryshnikova et al., 2008) although this technique 
presents challenges for measuring Ca2+ affinity (see below). 
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Conversely, our research group demonstrated that L29Q significantly increases the Ca2+ 
sensitivity of force generation using single skinned cardiac myocytes, but in a manner that 
was extremely sarcomere length dependent (Liang et al., 2008). Cardiac TnC F27W was used 
as a fluorescence reporter to monitor the in vitro Ca2+ binding and exchange with binding 
site II of cTnC. Our results showed that L29Q has a significantly increased Ca2+ binding 
affinity compared to the wild-type, and its response to sarcomere length change was 
significantly reduced. The increased Ca2+ sensitivity suggests that L29Q mutants bind Ca2+ 
more tightly and cause Ca2+ to dissociate more slowly from cTnC site II. Reduced length 
dependence of myofilament Ca2+ sensitivity likely influences the heart’s ability to regulate 
ventricular output in response to changes in ventricular filling (Liang et al., 2008). Overall, 
the heart is maintained in systole longer, resulting in diastolic dysfunction (Wen et al., 2008 
in Pinto et al., 2009). Changes in Ca2+ affinity is hypothesized to disrupt myocellular 
homeostasis, triggering Ca2+-regulated pathways leading to SCD (Baudenbacher et al., 2008) 
and/or hypertrophy (Heineke & Molkentin, 2006) as discussed later in this chapter. 
Choice of experimental techniques may account for the conflicting results. Compared to 
studies using single cardiac myocytes, ATPase and in vitro motility assays are excellent 
techniques for defining molecular interactions, but lack the geometric and mechanical 
constraints from other proteins within the sarcomere (Liang et al., 2008). Additionally, NMR 
techniques are limited in terms of accurate Ca2+ measurement as Ca2+ chelators, such as 
EGTA, cannot be utilized in NMR studies (Liang et al., 2008). The reduced length 
dependence of Ca2+ sensitivity is likely why other researchers, who had no or only marginal 
sarcomeric length control in their experimental techniques, have observed such variable 
results. Our experimental technique using single cardiac myocytes held at a constant 
sarcomere length may be more precise and closer to physiological conditions. Further to 
this, our work on cTnC and the L29Q mutation precedes the discovery of a human L29Q 
cTnC FHC patient. Salmonid cTnC has a greater than two-fold Ca2+ affinity over 
mammalian cTnC (Gillis et al., 2003) with four sequence differences between the 
mammalian and salmonid homologues responsible for the high Ca2+ affinity: D2N, V28I, 
L29Q, and G30D (NIQD). When the mammalian residues were mutated to the salmonid-
equivalent, including L29 to Q29, the Ca2+-binding affinities of the mammalian cTnC 
mutants increased to the level of the salmonid cTnC (Gillis et al., 2005). 
Seven years after the initial FHC cTnC report, a large study cohort of 1025 unrelated patients 
was screened for FHC mutations and four novel cTnC mutations were reported: A8V, C84Y, 
E134D and D145E (Landstrom et al., 2008). All four patients were symptomatic for FHC, 
with findings of syncope upon exertion (C84Y) and dyspnea and chest pain in the other 
three patients. They were all positive for varying degrees of ventricular hypertrophy. All 
were young or relatively young (17, 22, 37 and 58 years old) when diagnosed, but SCD was 
not reported in any patients or relatives. Functional analysis of the four variants using 
skinned porcine papillary fibres revealed increased Ca2+ sensitivity of force development for 
A8V, C84Y and D145E mutations, and A8V and D145E also showed increases in maximal 
force consistent with other in vitro studies of FHC-associated mutants (Landstrom et al., 
2008). Actomyosin ATPase activity in reconstituted thin filaments and spectroscopic 
properties of the four mutants confirmed increased myofilament Ca2+ sensitivity, except for 
E134D which was not significantly different from wild-type (Pinto et al., 2009). Isolated 
cTnC, Tn complex and thin filament assays, however, did not recapitulate the Ca2+ 
sensitivity findings observed in the reconstituted fibre assays, suggesting that the entire 
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reconstituted myofilament (that included the S1 myosin head) is required to recreate the 
increased Ca2+ sensitivity changes observed in skinned fibre assays. 
This research group also proposed that the D145E mutation influences regulation of 
contraction by disrupting Ca2+ binding to site IV of cTnC and demonstrated that this 
mutation reduced the cTnC ǂ helicity in the metal-bound state as determined by circular 
dichroism (Pinto et al., 2009). Another report investigated the effects of IAANS-labeled cTnC 
mutants on Ca2+ off-rate kinetics and concluded that both A8V and D145E mutations had 
significantly slower off-rate kinetics over the wild-type, suggesting that both mutations alter 
muscle relaxation properties by reducing ventricular filling time which correlates with the 
diastolic dysfunction seen in FHC patients (Pinto et al., 2011). 
Only one cTnC mutation so far has been directly linked to the SCD of a previously 
undiagnosed and asymptomatic 19 year old man who had a witnessed collapse while 
working at his computer (Chung et al., 2011). Autopsy revealed ventricular hypertrophy. 
Genetic testing of his family revealed a novel cTnC duplication at nucleotide 363, leading to 
a frameshift mutation at Q122A and causing a premature stop codon at position 30 in the 
new reading frame (Q122AfsX30) in 4 out of 7 relatives. The primary concern was for his 16 
year old genotype-positive, phenotype-negative sister, who can be monitored for disease 
manifestation (Chung et al., 2011). To date, no functional analysis has been done on this 
mutation finding. The premature stop codon created by this frameshift mutation is close to 
the C terminus, leading to speculation that the mutant protein is successfully translated, 
incorporated into the thin filament and creates adverse effects on Ca2+ sensitivity of force 
production similar to other cTnC mutations. One could also propose that the protein 
undergoes nonsense-mediated decay, leading to haploinsufficiency of cTnC within the 
cardiac myocytes. Future investigations will hopefully provide further insight to the 
pathogenic mechanisms of this newest cTnC mutation finding.  
5. Arrhythmogenic mechanisms in FHC 
Many studies comparing FHC phenotype with suspected underlying mechanisms are 
plagued by the lack of genotyping of cardiomyopathy patients, perhaps related to the high 
cost and time-consuming work of genetic testing. To address this issue, Colombo et al. 
(Colombo et al., 2008) argue that some genotype-phenotype correlations can provide 
important information to target DNA analyses in specific FHC candidate genes. Genetic 
testing may also clarify diagnosis and assist with optimal treatment strategies for more 
malignant phenotypes. In addition, genetic screening of first-degree relatives can assist in 
early identification and diagnosis of individuals at greatest risk for developing 
cardiomyopathy, allowing physicians to focus clinical resources on high-risk family 
members. Determining the underlying mechanism of SCD resulting from FHC remains 
elusive, though recent studies have begun to focus on the three cardinal manifestations of 
FHC separately (i.e. cardiac hypertrophy, myocyte disarray and fibrosis), as researchers are 
postulating that they may arise from distinct and independent mechanisms (Varnava, 
Elliott, Baboonian et al., 2001; Varnava, Elliott, Mahon et al., 2001; Wolf et al., 2005). Myocyte 
hypertrophy is postulated by some to increase arrhythmia vulnerability through intrinsic 
automaticity changes, as some studies demonstrate that hypertrophied myocytes exhibit 
pacemaker current up-regulation (re-expression) and action potential prolongation by 
down-regulation of the potassium transient outward Ito current (Sanguinetti, 2002 as cited in 
Wolf et al., 2005).  
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Triggered arrhythmias can occur as delayed after-depolarizations (DADs), early after-
depolarizations (EADs) or increased automaticity in non-ischemic FHC and are likely 
related to myocellular Ca2+ signalling and transport (Bers, 2008). DADs are commonly 
believed to be caused by spontaneous Ca2+ release from the SR that occurs as a consequence 
of high SR Ca2+ levels. This SR Ca2+ release causes a transient inward current (Iti) that can 
cause a threshold depolarization leading to an action potential. Several studies suggest that 
the Na+/ Ca2+ exchanger current (INCX) is responsible for Iti in human ventricular myocytes 
(Pogwizd et al., 2001). Further to this, Ter Keurs’ research group has been investigating 
myofilament arrhythmogenic Ca2+ release to determine if non-uniform excitation-
contraction coupling plays a role in the initiation of extra-systoles that create arrhythmias 
((Ter Keurs et al., 2006). Ter Keurs developed a model of non-uniform excitation-contraction 
using rat trabeculae and exposed a small muscle segment to BDM, a cross-bridge inhibitor 
(Backx et al., 1995 as cited in Ter Keurs et al., 2006), to recapitulate non-contracting 
myocardium as found in diseased hearts. Triggered propagating contractions were observed 
in the border zone of myocardium between non-contractile and contractile tissue when the 
trabeculae were stimulated to contract. The triggered contractions may be due to a quick 
release-induced Ca2+ dissociation from cTnC site II, leading to a local Ca2+ surge that is 
above the threshold for inducing Ca2+-induced Ca2+ release. This mechanism, referred to as 
“reverse excitation contraction coupling” (RECC), occurs when Ca2+ reuptake mechanisms 
have sufficiently recovered from the previous contraction during diastole (Boyden & ter 
Keurs, 2001). In FHC, the myocardium may have focal regions of non-uniformity due to 
structural anomalies, such as fibrosis or myocardial disarray, or perhaps due to electrical 
remodelling or gene dosage effects from Tn mutations. Increased Ca2+ binding to cTnC 
leading to a high Ca2+ buffering capacity may cause a large Ca2+ surge during rapid 
myofilament shortening during RECC. Hence, RECC may be an underlying pathological 
mechanism of arrhythmogenesis seen in FHC patients and warrants further investigation. 
Electrical alternans, in which there is alternating long and short action potential duration 
(APD), increases the risk of ventricular tachycardia that can degrade to ventricular 
fibrillation and SCD. The underlying mechanism may to be related to Ca2+ transient 
amplitude alternans. At high pacing frequencies, slow ryanodine receptor and/or Ca2+ 
current recovery may result in alternating SR Ca2+ release, due to alternating availability 
of ryanodine receptors (RyR). Prolonged Ca2+ transient decay rates, as seen in some 
transgenic FHC animal models may play a role here (see below). Spatially discordant 
alternans is thought to be a prerequisite to dangerous arrhythmias, as there is a non-
synchronous electrical substrate within the heart (Bers, 2008). Animal models support this 
hypothesis; increased myofilament Ca2+ sensitivity was associated with an 
arrhythmogenic substrate in transgenic cTnT mice, despite the absence of structural heart 
disease (Baudenbacher et al., 2008). Addition of a myofilament Ca2+ sensitizing agent, 
EMD, resulted in repolarization alternans at high pacing rates, beat to beat variation in 
APD, shorter effective refractory periods and increased spatial conduction velocity 
dispersion in wild-type cat and mouse hearts, paralleling the findings as observed in 
mutant cTnT I79N transgenic mice. Several mechanisms were proposed for the induction 
of ventricular tachyarrhythmias: increased Ca2+ binding to cTnC resulting in reduced Ca2+ 
transients with slower decay rates responsible for the shorter APD seen in transgenic I79N 
cTnT mice, and dysfunctional myocardial relaxation as seen in transgenic mice and in 
human patients also causing APD shortening. However, transgenic mice have differing 
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ion channel and Ca2+-handling protein expression from human hearts (Wetzel & Klitzner, 
1996). The high heart rates of mice, roughly 10 times faster than humans, can influence the 
refractory period associated with the incidence of arrhythmias, as mentioned previously. 
Additionally, studies of human HCM patients suggested that T-wave alternans (surface 
ECG recording associated with action potential alternans) may not be a useful SCD 
prediction tool (Fuchs & Torjman, 2009). 
5.1 Clinical findings in FHC patients 
It has proven difficult to elucidate the exact mechanisms linking FHC pathology and 
arrhythmogenicity in humans with limited access to fresh cardiac tissue from FHC 
patients. Studies currently utilize tissue from myectomy samples and explanted hearts in 
which there is profound disease phenotype. Thus, explorations of disease progression in 
pre-clinical patients are normally limited to non-invasive imaging techniques and 
electrophysiology. In addition, there is inherent patient referral bias for research studies 
as most FHC patients seen in surgical referral centres already have profound disease 
manifestation (Tardiff, 2011). 
Stored electrograms from implantable cardiac defibrillators indicate that SCD largely results 
from sustained ventricular tachycardia and/or ventricular fibrillation (B.J. Maron, 2010). 
One suggested trigger for SCD is sympathetic excitation, given that the initiating rhythm in 
many cases is sinus tachycardia, which may underlie the high SCD rate in athletes and sub-
adult FHC populations (Cha et al., 2007). Several studies of HCM patients wearing Holter 
monitors identified a higher rate of SCD for younger patients (age 30 and under) with non-
sustained ventricular tachycardia (NSVT) detected at least once during the 48 hour 
monitoring period. While NSVT is usually asymptomatic and frequently occurs during 
periods of increased parasympathetic (vagal) tone, it is associated with an increased SCD 
risk, especially in children and young adults (Elliott et al., 2000; Monserrat et al., 2003). 
However, most SCDs occur in patients without ambulatory ECG episodes of NSVT; clearly 
other contributory factors leading to risk of SCD are at play. A more recent study identified 
an increased SCD risk with ventricular arrhythmias triggered by exercise (Gimeno, Tome-
Esteban et al., 2009), which is more in keeping findings of triggered arrhythmias during 
sinus tachycardia, implicating sympathetic excitation during physical activity (Cha et al., 
2007). This is also in keeping with the in vitro experimental evidence of a blunted response 
to ǃ-adrenergic stimulation through phosphorylation of cTnI (i.e. reduced inhibitory 
response of phosphorylated cTnI on Ca2+ sensitivity for cTnC) and the resultant diastolic 
dysfunction as discussed previously. 
Cardiac magnetic resonance (CMR) imaging has allowed clinicians to precisely determine 
myocyte fibrosis and scarring in non-ischemic FHC, including phenotype-negative FHC 
patients who have experienced life-threatening arrhythmias (Makhoul et al., 2011; Strijack et 
al., 2008). Detection of fibrosis by late gadolinium enhancement in CMR is associated with 
increased propensity for VT on ambulatory ECG monitoring (Adabag et al., 2008) and is 
being considered as a clinical SCD risk marker (Maron, 2010). Fibrosis and scarring may 
promote localized zones of slowed conduction resulting in re-entrant arrhythmias (Cha et 
al., 2007). NMR imaging can detect focal or diffuse regions of fibrosis and hypertrophy 
morphologies that are missed by traditional echocardiography (M. S. Maron, 2009) and will 
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Myocyte disarray is another common feature in FHC patients and a recent study of 
myectomy samples from a small pediatric HCM cohort suggests that myocyte disarray has a 
significantly higher correlation with diastolic dysfunction than either hypertrophy or 
fibrosis (Menon et al., 2009). Extensive myocyte disarray has been linked to SCD in younger 
FHC patients (Varnava, Elliott, Mahon et al., 2001), especially those with cTnT mutations 
(Varnava, Elliott, Baboonian et al., 2001) in the absence of, or with minimal hypertrophy.  
6. Future considerations  
Of interest to investigators is the potential role of Ca2+ dysregulation in ER stress pathways. 
The SR in myocardial cells has long been thought to be the cardiac equivalent to ER with its 
main role as the intracellular regulator of Ca2+ fluxes and hence, excitation-contraction 
coupling in the heart. Some researchers propose that the SR contains a functional ER 
“compartment” with physiological roles such as protein synthesis, translocation and 
integration into membranes, folding and post-translational modifications including 
glycosylation and Ca2+ homeostasis (Mesaeli et al., 2001), although studies are lacking. ER 
stress occurs in response to environmental or genetic factors causing ER metabolic 
disturbances, accumulation of misfolded proteins, oxidative stress and/or depletion of ER 
Ca2+ stores. The “unfolded protein response” (UPR) is one mechanism by which the ER 
attempts to reestablish homeostasis by reducing protein expression, by increasing 
production of chaperones to handle accumulation of misfolded protein, promoting ER-
associated degradation to remove misfolded proteins (Schroder & Kaufman, 2005). This 
initial response of protein synthesis, suppression and upregulation of ER resident 
chaperones is designed to resolve the ER stress and enhance survival, but if the ER stress is 
severe or prolonged, the UPR may stimulate apoptosis (cell death). Do FHC mutations play 
a role in ER stress pathways, such as through Ca2+ dysregulation? Activation of the “fetal 
gene program” is a response to elevated Ca2+ to increase cardiac efficiency in the stressed 
heart. This response, unfortunately, also commonly results in detrimental cardiac 
hypertrophy (Eizirik et al., 2008; Wang et al., 2000). Elevated Ca2+ activates calcineurin A 
that dephosphorylates the transcription factor NFAT which translocates to the nucleus to 
stimulate cardiac remodelling and hypertrophy associated with the fetal gene program 
(Heineke & Molkentin, 2006). Other factors, such as MEF2, GATA and CamKII are also 
activated which initiate transcription programs associated with hypertrophy, remodelling 
and heart failure with increased risk of cardiac death (Molkentin et al., 1998). GATA-4 may 
play a significant role in FHC pathogenesis due to its ability to stimulate transcription of the 
cardiac-specific Tn genes (Liang et al., 2001; Molkentin & Olson, 1997; Molkentin et al., 
1998). Therefore, ER stress may turn on the fetal gene program in response to pathological 
insult. MicroRNAs (miRs) likely play a role in these regulatory processes with miRNA 
coding sequences often located within the newly transcribed genes (Eizirik et al., 2008; 
Wang et al., 2000). The hypothesis of elevated Ca2+ causing transcriptional activation of 
hypertrophy and perhaps pathological arrhythmia substrates (see below) is provocative and 
will likely continue to be an area of active investigation.  
Research into miRs that play a role in regulation of cardiac function and the recent findings 
that miR expression is deranged in cardiac disease may help to uncover the pathways to 
FHC disease progression and arrhythmogenesis. MiRs are short, non-coding RNA 
sequences that regulate expression of genes involved in orchestrating growth, development, 
function and stress responses in a spatio-temporal manner. MiRs target specific mRNA 
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sequences generally to inhibit protein expression, either by degradation of the bound 
mRNA target or by directly inhibiting translation of the mRNA sequence (Bartel, 2004). To 
date, there are at least 4 miRs shown to be involved in cardiac development, apoptosis and 
hypertrophy, namely: miR-1, miR-133, miR-208 and miR-499 (van Rooij et al., 2006). Several 
important target genes for miRs related to cardiac electrophysiology have been identified, 
including connexin 43 and inwardly-rectifying potassium channel Kir2.1 (Zhao et al., 2007) 
and miR-1 expression changes have been associated with arrhythmogenesis due to up-
regulation or down-regulation of these gene products (Girmatsion et al., 2009; Yang et al., 
2007). Recent studies are beginning to elucidate the link between miRs and SCD due to 
arrhythmias by identifying the effects of altered expression levels of miRs in the heart on 
cardiac conduction and excitability (Callis et al., 2009; Matkovich et al., 2010; Zhao et al., 
2007). A database has been developed online (http://www.mir2disease.org/) for miRs 
involved in human disease, including FHC. 
Sudden Infant Death Syndrome (SIDS) refers to the sudden death of an infant under 1 year 
of age which remains unexplained after a thorough medicolegal investigation (Willinger et 
al., 1991). Researchers are now considering inherited cardiac arrhythmia syndromes in its 
etiology. Recent research has revealed that up to 20% of SIDS cases may be associated with 
inheritable arrhythmia syndromes, such as long QT syndrome (Klaver et al., 2011). Given 
that FHC is the most common cause of SCD in young individuals, it stands to reason that 
some infants may die from SCD attributed to FHC. Further to this, as discussed earlier, 
some Tn mutants, particularly the cTnT mutants, have negligible or mild hypertrophy that 
may not be observed grossly during the post mortem exam. To date, only one study has 
screened SIDS cases for FHC mutations (Brion et al., 2009). Their findings of 14 cases with 7 
genetic variants from 4 different FHC genes, including cTnT and cTnI, from 140 SIDS tissues 
suggests that some SIDS cases may be associated with FHC-causing mutations. The 
relatively recent emergence of FHC-associated Tn (in particular, cTnC) gene mutations make 
these candidate genes previously unrecognized and perhaps under-represented factors to be 
considered in future SIDS investigations. Besides SIDS cases, how many FHC mutation 
positive cases have gone unrecognized in post mortem investigations following the sudden, 
unexpected death of children and young adults? 
7. Conclusions 
Sudden cardiac death affects approximately 1-2% of children and adolescents, and up to 1% 
of young adults in FHC-affected populations. In vitro analysis of single molecule mechanics 
and reconstituted skinned myocytes have identified intracellular Ca2+ dysregulation, altered 
myofibrillar Ca2+ sensitivity and altered energy metabolism as potential mechanisms at the 
sarcomere and cellular level. Animal models incorporating specific FHC mutations have 
broadened our understanding of the pathogenesis of FHC, including structural and 
electrophysiological remodelling associated with the arrhythmogenic substrate. There are, 
however, caveats to using in vitro and animal model analyses, given that some may not 
necessarily recapitulate the physiological substrate in human FHC patients. Most models, 
however, share a consistent molecular phenotype, namely increased myofilament Ca2+ 
sensitivity and increased energetic cost of force development, that underlies the complex 
and heterogeneous phenotype that exists at the human patient level. Other genetic, 
environmental and biological factors such as age, lifestyle and other health issues are also 
likely disease-modifying factors. Research into molecular approaches and post-translational 
www.intechopen.com
  
Cardiomyopathies – From Basic Research to Clinical Management 
 
294 
mechanisms associated with FHC, including effects of phosphorylation and a potential role 
in ER stress mechanisms, will likely continue to elucidate the link between genotype and 
phenotype. 
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